Masafumi Ikeda

National Cancer Center Hospital East — Japan

Medicine · Health Sciences

76h-index33.3kcitations1.0kworks4.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(312), Hepatocellular Carcinoma Treatment and Prognosis(284), Cholangiocarcinoma and Gallbladder Cancer Studies(224), Neuroendocrine Tumor Research Advances(115), Colorectal Cancer Treatments and Studies(115)

Publications1.0k total

Change in Liver Function after Selective Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: JIVROSG-2001 PRESIDENT-ALBI – A Secondary Analysis of a Multicenter Randomized Controlled Trial
Liver Cancer·2025Open Access
Data from E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma
2025Open Access
Data from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
2025Open Access
Supplementary Data 1 from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
2025Open Access
Supplementary Data 1 from E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma
2025Open Access
Durvalumab plus gemcitabine-cisplatin versus S-1 plus gemcitabine-cisplatin in advanced biliary tract cancer: a comparative study
ESMO Gastrointestinal Oncology·2025Open Access
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers
Liver International·2025· 3 citedOpen Access
Targeted Therapy Improves Real-World Survival in Patients with Molecularly Matched Advanced Biliary Tract Cancer
2025Open Access
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab
European Journal of Cancer·2025
Recent Trends and Patient Outcomes of Phase I Trials: A Single-Institution Experience in the Era of New Therapeutic Agents
JCO oncology advances.·2025Open Access
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
Clinical Cancer Research·2025· 1 cited
Multicenter Retrospective Study of Efficacy of Systemic Therapy in Patients with Neuroendocrine Tumor Grade 3 (JOSC-2001)
Neuroendocrinology·2025Open Access
E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma
Clinical Cancer Research·2025· 1 citedOpen Access
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial
Journal of Clinical Oncology·2025· 10 citedOpen Access
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis
Liver Cancer·2025Open Access
Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results
Zeitschrift für Gastroenterologie·2025
Analysis of clinically actionable alterations in baseline tumor versus plasma samples in participants of the TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer
Zeitschrift für Gastroenterologie·2025
1507P Phase I study of ERY974 + atezolizumab (atezo) + bevacizumab (bev) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC)
Annals of Oncology·2025
Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity score-matched analysis
Pancreatology·2025
Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study
Japanese Journal of Clinical Oncology·2025· 1 citedOpen Access
page 1 of 51Next →

Frequent Co-authors

Takuji Okusaka(29), Masatoshi Kudo(22), Junji Furuse(14), Chigusa Morizane(11), Makoto Ueno(11), Ann‐Lii Cheng(10), Richard S. Finn(9), Ho Yeong Lim(8), Hideki Ueno(8), В. В. Бредер(7), Philippe Merle(7), Andrew X. Zhu(7), Kazuomi Ueshima(7), Namiki Izumi(7), Nobumasa Mizuno(7), Peter R. Galle(6), Wendy Verret(6), Hiromitsu Kumada(6), Hiroshi Ishii(6), Shukui Qin(5)